Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Eleonora Gelli"'
Autor:
Ludovica Calabretta, Chiara Valsecchi, Marianna Rossi, Elisa Roncoroni, Stefania Croce, Elisa Lenta, Claudia Patricia Tobar, Eleonora Gelli, Gianluca Martini, Patrizia Zappasodi, Marco Zecca, Maria Antonietta Avanzini, Luca Arcaini
Publikováno v:
HemaSphere, Vol 7, p e010520e (2023)
Externí odkaz:
https://doaj.org/article/ec65e41a690e4f1ab1a2ec378d81a6cd
Autor:
Gianluca Martini, Patrizia Zappasodi, Virginia Valeria Ferretti, Ludovica Calabretta, Eleonora Gelli, Claudia Patricia Tobar Cabrera, Marianna Rossi, Elisa Roncoroni, Luca Arcaini
Publikováno v:
HemaSphere, Vol 7, p e90440f4 (2023)
Externí odkaz:
https://doaj.org/article/256aae49535b425c968c4921aba6a031
Autor:
Simona De Gregori, Eleonora Gelli, Mara Capone, Giulia Gambini, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Gianluca Martini, Ludovica Calabretta, Luca Arcaini, Riccardo Albertini, Patrizia Zappasodi
Publikováno v:
Pharmaceutics, Vol 15, Iss 6, p 1680 (2023)
The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for int
Externí odkaz:
https://doaj.org/article/e2a21e6e6a1745e9907f7d91eb3174cc
Autor:
Gabriele Merati, Marianna Rossi, Anna Gallì, Elisa Roncoroni, Silvia Zibellini, Ettore Rizzo, Daniela Pietra, Cristina Picone, Barbara Rocca, Claudia Patricia Tobar Cabrera, Eleonora Gelli, Eugenio Santacroce, Luca Arcaini, Patrizia Zappasodi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Acute leukemia of ambiguous lineage (ALAL) is a rare type of leukemia and represents an unmet clinical need. In fact, due to heterogeneity, substantial rarity and absence of clinical trials, there are no therapeutic guidelines available. We investiga
Externí odkaz:
https://doaj.org/article/eab51768fab14e468d4f14307f1fa62d
Autor:
Zappasodi, Simona De Gregori, Eleonora Gelli, Mara Capone, Giulia Gambini, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Gianluca Martini, Ludovica Calabretta, Luca Arcaini, Riccardo Albertini, Patrizia
Publikováno v:
Pharmaceutics; Volume 15; Issue 6; Pages: 1680
The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for int
Autor:
Patrizia Zappasodi, Simona De Gregori, Eleonora Gelli, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Eugenio Santacroce, Gianluca Martini, Ludovica Calabretta, Riccardo Albertini, Luca Arcaini
Publikováno v:
Blood. 140:11528-11529
Autor:
Marianna Rossi, Maria Elena Nizzoli, Anna Gallì, Elisa Roncoroni, Silvia Zibellini, Gabriele Merati, Ettore Rizzo, Barbara Rocca, Daniela Pietra, Cristina Picone, Marco Brociner, Claudia Patricia Tobar Cabrera, Eleonora Gelli, Eugenio Santacroce, Luca Arcaini, Patrizia Zappasodi
Publikováno v:
American Journal of Hematology. 97
Autor:
Giada Rotunno, Ayalew Tefferi, Emanuela Sant'Antonio, Carmela Mannarelli, Giacomo Coltro, Lara Mannelli, Simone Romagnoli, Alessandro M. Vannucchi, Paola Guglielmelli, Eleonora Gelli, Niccolò Bartalucci, Enrica Ravenda, Sara Fiaccabrino, Mrinal M. Patnaik
Publikováno v:
Blood Adv
The dysregulation of the JAK/STAT pathway drives the pathogenesis of myelofibrosis (MF). Recently, several JAK inhibitors (JAKis) have been developed for treating MF. Select mutations (MTs) have been associated with impaired outcomes and are currentl